Item 8.01 Other Events.

On January 7, 2022, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release (the "Press Release") with Regeneron Pharmaceutical Inc. (Nasdaq: REGN) announcing that the parties have entered into a license and collaboration agreement for the Company to clinically develop, commercialize and distribute Evkeeza® (evinacumab) in countries outside of the United States. A copy of the Press Release is filed as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No. Description
99.1          Press Release, dated January 7, 2022.
104         The cover page from the Company's Current Report on Form 8-K dated
            January 7, 2022 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses